Literature DB >> 7853527

Spontaneous reversion of human immunodeficiency virus type 1 neutralization-resistant variant HXB2thr582: in vitro selection against cytopathicity highlights gp120-gp41 interactive regions.

T L Stern1, M S Reitz, M Robert-Guroff.   

Abstract

Spontaneous revertants of the immune-selected variant HXB2thr582, which resists neutralization by certain conformationally dependent antibodies specific for the CD4-binding site on gp120 (such as F105), appeared after long-term culture in the absence of immune-selecting serum. Molecular analysis showed some of the viruses in the revertant stock contained a simple back mutation, whereas others retained the Thr-582 codon but contained a substitution of serine for phenylalanine in gp41 at position 673. Neutralization sensitivity to the selecting serum and to F105 of infectious clones containing either the back mutation or the compensatory mutation, HXB2thr582ser673, was confirmed. HXB2thr582-infected cells have a greater propensity for syncytium formation and single cell killing than do either the parental HXB2 or the revertant HXB2thr582ser673. This suggests that the revertant arose by selection in vitro for a less cytopathic virus. Our results link three envelope regions shown to influence virus-cell fusion as well as neutralization by antibody: the CD4-binding region, the leucine zipper domain, and a region hidden to antipeptide antibodies upon envelope oligomerization. Taken together they illustrate the functional importance of the gp120-gp41 interaction and emphasize the impact of the interplay between envelope regions on overall conformation and function and on recognition by neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7853527      PMCID: PMC188797     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  Changes in the transmembrane region of the human immunodeficiency virus type 1 gp41 envelope glycoprotein affect membrane fusion.

Authors:  E Helseth; U Olshevsky; D Gabuzda; B Ardman; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

2.  Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41.

Authors:  E O Freed; D J Myers; R Risser
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

3.  Sequencing products of the polymerase chain reaction directly, without purification.

Authors:  S J Meltzer; S M Mane; P K Wood; L Johnson; S W Needleman
Journal:  Biotechniques       Date:  1990-02       Impact factor: 1.993

4.  Retroviral envelope glycoproteins contain a "leucine zipper"-like repeat.

Authors:  E L Delwart; G Mosialos; T Gilmore
Journal:  AIDS Res Hum Retroviruses       Date:  1990-06       Impact factor: 2.205

5.  Unexpectedly high levels of HIV-1 RNA and protein synthesis in a cytocidal infection.

Authors:  M Somasundaran; H L Robinson
Journal:  Science       Date:  1988-12-16       Impact factor: 47.728

6.  An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection.

Authors:  M R Posner; T Hideshima; T Cannon; M Mukherjee; K H Mayer; R A Byrn
Journal:  J Immunol       Date:  1991-06-15       Impact factor: 5.422

7.  Attenuation of human immunodeficiency virus type 1 cytopathic effect by a mutation affecting the transmembrane envelope glycoprotein.

Authors:  M Kowalski; L Bergeron; T Dorfman; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

8.  The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope.

Authors:  C Wilson; M S Reitz; K Aldrich; P J Klasse; J Blomberg; R C Gallo; M Robert-Guroff
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

9.  Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain.

Authors:  E O Freed; D J Myers; R Risser
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

10.  Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.

Authors:  J Albert; B Abrahamsson; K Nagy; E Aurelius; H Gaines; G Nyström; E M Fenyö
Journal:  AIDS       Date:  1990-02       Impact factor: 4.177

View more
  7 in total

1.  Substitutions in the receptor-binding domain of the avian sarcoma and leukosis virus envelope uncouple receptor-triggered structural rearrangements in the surface and transmembrane subunits.

Authors:  R Damico; L Rong; P Bates
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HR2) of gp41.

Authors:  Wei Wang; Christopher J De Feo; Min Zhuang; Russell Vassell; Carol D Weiss
Journal:  J Virol       Date:  2011-10-12       Impact factor: 5.103

3.  Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages.

Authors:  Kieran Cashin; Michael Roche; Jasminka Sterjovski; Anne Ellett; Lachlan R Gray; Anthony L Cunningham; Paul A Ramsland; Melissa J Churchill; Paul R Gorry
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

4.  Residues in the gp41 Ectodomain Regulate HIV-1 Envelope Glycoprotein Conformational Transitions Induced by gp120-Directed Inhibitors.

Authors:  Beatriz Pacheco; Nirmin Alsahafi; Olfa Debbeche; Jérémie Prévost; Shilei Ding; Jean-Philippe Chapleau; Alon Herschhorn; Navid Madani; Amy Princiotto; Bruno Melillo; Christopher Gu; Xin Zeng; Youdong Mao; Amos B Smith; Joseph Sodroski; Andrés Finzi
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

5.  Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.

Authors:  L T Rimsky; D C Shugars; T J Matthews
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

6.  Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites.

Authors:  B A Watkins; S Buge; K Aldrich; A E Davis; J Robinson; M S Reitz; M Robert-Guroff
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer.

Authors:  Q J Sattentau; J P Moore
Journal:  J Exp Med       Date:  1995-07-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.